Palisade Bio announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis, UC, therapy. The collaboration with Strand Life Sciences provides Palisade Bio access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors. Leveraging data from over ten UC clinical studies, Palisade has curated a pipeline of 1600 UC patient samples, including transcriptomics and clinical outcomes. This curated dataset, analyzed using in-house tools, enables Palisade to identify biomarkers for selecting UC patient responders, utilizing machine learning to develop a precision medicine approach to patient selection.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
- Palisade Bio demonstrates bioactivation of PALI-2108
- Palisade Bio to Participate in the Virtual Investor Lunch Break Event
- Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
- Palisade Bio presents development overview of PALI-2108
